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ABSTRACT
Objective: The study was aimed to evaluate the adequacy of information provided by drug promotional literature using WHO criteria. They were also 
evaluated for the quality, types of claims and the genuineness of these claims in this literature.
Methods: 412 drug promotional literature were collected from 20 busy physicians in the western part of Chennai from their private clinics. In addition 
to carrying out of “WHO criteria, 1988,” the brochures were examined for the quality of coverage using a pre-tested and pre-validated checklist and 
types of claims and the genuineness of these claims were evaluated for their recoverability and accuracy.
Results: It was found that all the WHO criteria were not fulfilled by any of the promotional literature. 91.2% of leaflets satisfied the 4 WHO criteria 
namely, the brand name, generic name, approved therapeutic uses, name and address of the manufacturer. A most neglected aspect of drug promotion 
was information regarding drug interactions, precautions, Adverse drug reactions and overdosage (<10%). Of 412 leaflets collected, the quantitative 
research methods were mentioned in 67 (16.2%). Cardiovascular drugs and nutritional supplements were the most promoted drug groups (23% and 
17%, respectively). 412 drugs promotional literature made a total of 954 claims. References were cited in 47% of the literature of which 96% were 
from the indexed journal and were retrievable.
Conclusion: Drug promotional literature analyzed by this study was inadequate in terms of their adequacy, quality and genuineness of coverage. 
Thus, the pharmaceutical companies did not follow the WHO guidelines while promoting their products, thus aiming to satisfy their commercial 
motive rather than fulfilling the educational aspect of promotion.
Keywords: Promotional literature, Ethical criteria for drug promotion, Pharmacy practice, marketing practice.
INTRODUCTION
The important sources of information on any new drug include 
textbooks, briefings by medical representatives, journal manuscripts, 
product monograms from pharmaceutical companies, drug 
promotional literature, etc. According to World Health Organization’s 
(WHO) criteria for promotion of medical drugs, “promotion refers to 
all the informational and persuasive activities of manufacturers and 
distributors, the effect of which is to induce the prescription, supply, 
purchase and/or use of medicinal drugs” [1]. Drug promotional 
literature distributed by pharmaceutical companies is an important 
source of prescribing information to the doctor, and the main aim of 
pharmaceutical advertisements is to persuade physicians to prescribe 
the product that is promoted, [2]. One of the major marketing strategies 
of pharmaceutical companies is “direct to physician marketing” [3,4]. 
The drug promotional literature should provide relevant research 
findings regarding the drug. The validity of research findings, its 
critical appraisal is often ascertained by the physician depending on 
the adequacy of the information provided in the promotional literature. 
There are ethical guidelines that need to be followed for the promotion 
of drugs at the national, as well as the international level. There are 
two important guidelines that are to be followed for the regulation 
of drug promotional activities at the international level; they are the 
Ethical criteria for medicinal drug promotion by WHO [1] and the Code 
of Pharmaceutical Marketing Practices by International Federation of 
Pharmaceutical Manufacturers Association [5]. The majority of the 
drug promotional activities in India are governed by the Organization 
of Pharmaceutical Producers of India, which is a self-regulatory 
code of pharmaceutical marketing practices [6]. The pharmaceutical 
companies targets doctors/prescribers through visits on a weekly or 
monthly basis, distributing attractive, eye-catching brochures that are 
often misleading and confusing [7]. Improper advertisement of drugs 
encourages drug consumerism instead of the rational use of drugs. 
Moreover, a strong regulatory system is absent in developing countries 
to keep a check on such activities.
In India, very few studies regarding the quality, adequacy, and 
genuineness of the scientific information provided in the promotional 
literature of drugs that are being distributed by pharmaceutical 
companies have been carried out [8]. Therefore, this study has been 
taken up with the aim to analyze the drug promotional literature in 
terms of these three parameters.
Aims and objectives
With this background, this study was carried out to evaluate the drug 
promotional literature in accordance with the WHO criteria and also to 
evaluate the quality, types of claims and the genuineness of these claims 
with the hope that it might help the physicians to find out as to what 
extent they may rely on this source of information.
METHODS
The study was conducted as an observational, cross-sectional study in 
the outpatient department of 20 busy physicians in the western part of 
Chennai. A total of 412 drug promotional literature (brochures) were 
collected randomly from 20 busy physicians from their private clinics 
for a period of 1-month starting from 1st June to 30th June 2014. The 
primary screening process was carried out on all promotional literature 
collected and literature that promotes modern medicines, where at 
least one therapeutic claim were observed, was taken for the analysis in 
this study. Those literatures promoting medicinal equipment’s (blood 
glucometer, insulin pump, etc.) and devices (tongue depressors, medical 
thermometers, etc.) and orthopedic prosthesis, product monographs, 
Ayurvedic and Siddha medicines, reminder advertisements (they do 
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not present any therapeutic information), were all excluded from the 
analysis [9]. Ethical medicinal drug promotion criteria by WHO, which 
sites what information the drug promotional literature should contain 
was used for the analysis of the adequacy of coverage. A pre-tested 
and pre-validated checklist with nine parameters representing the 
quantitative analysis method was used for the analysis of the quality 
of the promotional literature [10]. The validity of the claims that were 
made in drug promotional literature were cross-checked by referring 
to standard literature online, listed in databases such as PubMed, 
Medline and Cochrane reviews, standard textbooks and peer-reviewed 
journals [11]. The references mentioned in this literature were also 
evaluated for their authenticity and retrievability.
RESULTS
A total of 486 drugs were promoted in 412 drug promotional literature. 
Of the 486 drugs promoted, 185 (38%) were single drug formulation 
and 301 (62%) fixed dose combinations (Fig. 1). Most commonly 
promoted group of drug was cardiovascular 112 (23%) followed 
by nutritional supplements 83 (17%), miscellaneous 59 (12.1%), 
antibiotics 56 (11.6%), hormones and antidiabetics 48 (9.8%), 
obstetrics and gynecology 41 (8.4%), non-steroidal anti-inflammatory 
drugs 35 (7.2%), gastrointestinal tract drugs 32 (6.6%) and respiratory 
system drugs 20 (4.1%) (Fig. 2).
From the 412 drug promotional literature collected, it was found that 
none of the brochures fulfilled all the 11 WHO criteria. The brand 
name was mentioned in all the drug promotional literature, whereas 
the generic name was found in 99.27%. Approved therapeutic use of 
the drug was mentioned in 393 (95.3%) drug promotional literature. 
91.2% of leaflets satisfied the 4 WHO criteria, namely, the brand name, 
generic name, approved therapeutic uses, name and address of the 
manufacturer. Of all the literature, the most neglected aspects of drug 
promotion was information about drug interactions, precautions, 
adverse drug reactions and over dosage (<10%). Detailed analysis of 
fulfillment of WHO criteria are given in Table 1.
Of 412 drug promotional literature, research findings by quantitative 
methods were mentioned in only 67 (16.2%). Drug to drug 
comparison and “p” value was mentioned in 51 and 44, respectively. 
The confidence interval for the samples was obtained using SPSS 
software. Randomization and blinding status were mentioned in 36 
and 29, respectively. The power of the study was mentioned in six and 
confidence interval was mentioned in seven. The quality of coverage 
with reference to the reporting of quantitative research findings is 
shown in Table 2.
Pharmaceutical companies also made multiple claims in the literature, 
apart from giving therapeutic information, it was observed that on 
an average two claims were made per literature i.e., 954 claims were 
made in 412 drug promotional literature (2.31 per literature). Claims 
about efficacy were made in 91% of the literature. 72.08% claims were 
supported with scientific references. The majority of references cited 
were from journal articles followed by monographs, books, case reports. 
References were cited in 47% of the literature of which 96% were from 
the indexed journal. The genuineness of scientific information is shown 
in Table 3.
DISCUSSION
It is observed that there is more of a commercial relationship between 
the prescriber and the pharmaceutical company, in the drug promotional 
activity that are being carried out [9]. The therapeutic information 
given in this literature was more of a bias than to help physicians reach 
a rationalized decision about the drug that was being promoted. These 
literature were full of claims regarding safety or efficacy that were not 
supported with proof or rather unsubstantiated, and the claims were 
therapeutically irrelevant also [3]. There is evidence that these kinds 
of drug promotional practices can negatively affect both patients and 
the healthcare professionals. The inferences from this study illustrated 
that the reporting quality of numerous parameters in the promotional 
Fig. 1: Classification as per type of drug formulation (n=486)
Fig. 2: Types of drugs promoted in the literature (n=486)
Table 1: Analysis of literature according to WHO criteria 
n=412 (adequacy of coverage)





Brand name 412 100
Content of active ingredient (s) 359 87.1
Adjuvant 5 1.21
Approved therapeutic uses 393 95.3
Dosage form or regimen 365 88.6
Side effects and adverse reactions 37 9.8
Precautions, contraindications 34 8.25
Major interactions 22 5.33
Manufacturer’s name and address 381 92.4
Reference to scientific literature 194 47
INN: International non-proprietary name
Table 2: Analysis of various parameters of quantitative 
research (quality of coverage)









Drug to drug comparison 51 12.38 76.12 74.35-77.89
Random assignment 36 8.74 53.73 51.96-55.5
Blinding status 29 7.04 43.28 41.51-45.05
p-value given 44 10.68 65.67 63.9-67.44
Comparability of groups 3 0.73 4.48 2.71-6.25
All accounted for or ITT 4 0.98 5.97 4.2-7.74
ARR/NNT reported 31 7.52 46.27 44.5-48.04
Power mentioned 6 1.46 8.95 7.18-10.72
Confidence interval 
mentioned
7 1.7 10.45 8.68-12.22
ITT: Intention to treat, ARR: Absolute risk reduction, NNT: Number needed to 
treat
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literature of drugs promoted by pharmaceutical companies is not in 
line with the standards. Therapeutically irrelevant information was 
printed, compromising space that would have been used to cite more 
important scientific information. This unethical drug promotional 
literature phenomenon is not confined only to India but has been under 
observation in medical journals of other countries also [12,13].
In this study, the generic name was mentioned in 99.27% drug 
promotional literature. In most of the literature, the generic name was 
mentioned in small letters than the brand name. The most neglected 
aspect of drug promotion was information about drug interactions, 
precautions, adverse drug reactions and overdosage (<10%), and also 
coincides with a similar study carried out in other parts of India [3]. 
The price of the drug was not mentioned in most of the literature. These 
findings suggest that unethical drug promotion is widespread in India, 
as well as all over the world and confuses the physician in making a 
decision regarding rational prescription of drugs. The quality of paper, 
print, and color were excellent in all (100%) literatures in our study. In 
India, there are regional Ethics Committees at Mumbai, Delhi, Chennai 
and Chandigarh to collect complaints against drugs that are promoted 
unethically by advertisements. These complaints are then forwarded 
to the drug controller authority which then takes necessary legal steps 
against drug manufacturers and distributors [7]. Therefore, it is the 
responsibility of a practicing physician to be aware of the downfalls 
in a drug promotional literature before taking it as a scientific source 
of information, and any flaws, if identified, should be reported to the 
appropriate authority [14].
This study evaluates the promotional activity of printed promotional 
literature used by pharmaceutical companies; however, interventional 
research is needed to verify the awareness levels of the physicians 
about these facts, and updating the physicians will help them gain 
ethical and only information that is accurate from promotional 
literature [3]. Combined efforts of physicians, regulatory authority and 
pharmaceutical industries can definitely help with ethical promotion of 
a drug and rational prescribing.
CONCLUSION
Drug promotional literature analyzed in this study was inadequate in 
terms of their adequacy, quality and genuineness of coverage. Hence, it 
can be concluded that the majority of the drug promotional literature 
that are given to the prescribers are not able to spread awareness 
towards rational prescribing, but only promote the drug and have 
commercial benefits.
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Table 3: Analysis of genuineness of scientific information 
n=412 (genuineness of coverage)
Parameter Number of samples Percentage
Authentic 123 29.9
Exaggerated 114 27.67
Controversial 95 23.1
Misrepresentation 52 12.62
False 28 6.8
